CureVac
CVAC
CVAC was delisted on the 5th of January, 2026.
83 hedge funds and large institutions have $21.8M invested in CureVac in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
40% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 20
15% more call options, than puts
Call options by funds: $329K | Put options by funds: $286K
11% more funds holding
Funds holding: 75 → 83 (+8)
0.01% more ownership
Funds ownership: 3.5% → 3.51% (+0.01%)
18% less capital invested
Capital invested by funds: $26.6M → $21.8M (-$4.78M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.07M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$926K |
| 3 |
Millennium Management
New York
|
+$591K |
| 4 |
SOW
State of Wyoming
Cheyenne,
Wyoming
|
+$398K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.71M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.5M |
| 3 |
BlackRock
New York
|
-$420K |
| 4 |
Goldman Sachs
New York
|
-$264K |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$256K |
CVAC Hedge Fund Activity: Q1 2025 in Review
83 institutional investors reported a position in CureVac (CVAC) for Q1 2025, worth a combined $21.8M — down 18% from $26.6M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CVAC positions and 10 closed out — a net gain of 8 holders — while 28 added to existing stakes and 20 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $1.07M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.71M sold.
- 83 institutional investors held CureVac (CVAC) as of Q1 2025, up from 75 in Q4 2024.
- Funds reported $21.8M of CureVac stock for Q1 2025, down 18% quarter-over-quarter.
- 18 funds opened new CureVac positions in Q1 2025 and 10 closed out, a net change of +8 holders.
- The largest CureVac buyer in Q1 2025 was GSA Capital Partners, an estimated $1.07M added.
- The largest CureVac seller in Q1 2025 was Alyeska Investment Group, an estimated $1.71M sold.
Based on aggregated 13F filings for Q1 2025.